Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29223447 | 0.93 | CRBN (0.62) | CRBNDDB1GPR119HRH3POLB | |
| SCHEMBL30830933 | 0.90 | CRBN (0.55) | CRBNDDB1GPR119POLBCHEK2 | |
| SCHEMBL30830846 | 0.90 | DDB1 (0.54) | CRBNDDB1GPR119HRH3 | |
| SCHEMBL30830575 | 0.81 | DDB1 (0.61) | CRBNDDB1GPR119HRH3 | |
| SCHEMBL25074070 | 0.81 | DDB1 (0.60) | CRBNDDB1GPR119 | |
| SCHEMBL30201818 | 0.81 | DDB1 (0.60) | CRBNDDB1GPR119 | |
| SCHEMBL24206650 | 0.81 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL23301622 | 0.81 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL25187964 | 0.81 | CRBN (0.67) | CRBNDDB1GPR119POLB | |
| SCHEMBL30830975 | 0.80 | DDB1 (0.54) | CRBNDDB1GPR119HRH3CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |